The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use
Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.
EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval
EP: 2.An Overview of Adalimumab Biosimilars
EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars
EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases
EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings
EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars
EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice
EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients
EP: 9.Switching From Adalimumab to a Biosimilar
EP: 10.Clinical Experience With Initiating Adalimumab Biosimilars
EP: 11.The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use
EP: 12.Copay Assistance Programs for Adalimumab Biosimilars
EP: 13.Common Questions From Patients About Adalimumab Biosimilars
EP: 14.The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars
EP: 15.Resources for Patients and Providers on Adalimumab Biosimilars
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
The discussion centers on how healthcare professionals can promote the use of adalimumab biosimilars and enhance patient care. The consensus is that biosimilars offer comparable efficacy and safety to the originator drug, with improved accessibility for patients. Encouragingly, dermatologists, among others, are being urged to consider these options for their patients.
Healthcare professionals emphasize the importance of patient education and cost savings as key factors in promoting biosimilar adoption. Educating both providers and patients about biosimilars, including their regulatory approval process and safety profile, is essential for widespread acceptance. Financial considerations, such as copay savings, also play a significant role in patient decision-making.
Overall, the aim is to assure patients of the efficacy and safety of biosimilars and to equip healthcare providers with the knowledge needed to support their use effectively.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
